Zacks Investment Research on MSN

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The stock has also outperformed the sector and the S&P 500 Index during this time ...
AFN

Bayer’s 117bn data points and decade-old data culture drive AI advantage, says CIO

Bayer is deploying GenAI tools at scale while many corporates struggle to find ROI on AI. The difference may lie in a 12-year ...
PharmTech

Live Cell High-Content Imaging is Driving Drug Discovery

Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...